Last reviewed 2026-04-19 · How we verify

JNJ-38877618: Part 1a

Janssen Cilag N.V./S.A. · Phase 1 active Small molecule

JNJ-38877618: Part 1a is a Small molecule drug developed by Janssen Cilag N.V./S.A.. It is currently in Phase 1 development.

At a glance

Generic name	JNJ-38877618: Part 1a
Sponsor	Janssen Cilag N.V./S.A.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JNJ-38877618: Part 1a CI brief — competitive landscape report
JNJ-38877618: Part 1a updates RSS · CI watch RSS
Janssen Cilag N.V./S.A. portfolio CI

Frequently asked questions about JNJ-38877618: Part 1a

What is JNJ-38877618: Part 1a?

JNJ-38877618: Part 1a is a Small molecule drug developed by Janssen Cilag N.V./S.A..

Who makes JNJ-38877618: Part 1a?

JNJ-38877618: Part 1a is developed by Janssen Cilag N.V./S.A. (see full Janssen Cilag N.V./S.A. pipeline at /company/janssen-cilag-n-v-s-a).

What development phase is JNJ-38877618: Part 1a in?

JNJ-38877618: Part 1a is in Phase 1.

Manufacturer: Janssen Cilag N.V./S.A. — full pipeline
Compare: JNJ-38877618: Part 1a vs similar drugs
Pricing: JNJ-38877618: Part 1a cost, discount & access